402 Resources in

Medshorts

By month
Cardiac
2 Min Read
14 Jun

Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with ULMCA lesions

According to a recent study, intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) has led to enhanced clinical outcomes and a significantly diminished risk of major adverse cardiovascular events (MACE) among patients having unprotected left main coronary artery (ULMCA) lesions . This study’s results were published in the journal, Coronary artery disease.

This randomized clinical study included 181 patients with ULMCA lesions who were scheduled to undergo drug-eluting stent implantation. The patients were divided into two groups: 90 patients in the IVUS-guided group and 91 patients in the conventional group. The study evaluated clinical outcomes, procedural characteristics, and the occurrence of MACE for all patients. A multivariate Cox regression analysis was performed to assess the risk reduction associated with IVUS-guided PCI.

Patients who were subjected to IVUS exhibited significantly higher pre-dilatation before stenting (88.9% vs. 72.5%), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3), pressure for post dilatation (18 ± 3 vs. 16 ± 2), and post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49). In terms of 12-month outcomes, patients who received IVUS showed significantly lower MACE compared to those who underwent the conventional method (3.3% vs. 18.7%). Multivariate Cox regression analysis indicated that IVUS was associated with an 84.4% risk reduction in 1-year MACE.

The above study demonstrated that IVUS-guided PCI resulted in enhanced clinical outcomes and substantially lowered the risk of MACE in patients with ULMCA lesions when compared to angiographic-guided PCI.

Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with ULMCA lesions

According to a recent study, intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) has led to enhanced clinical outcomes and a significantly diminished risk of major adverse cardiovascular events (MACE) among patients having unprotected left main coronary artery (ULMCA) lesions . This study’s results were published in the journal, Coronary artery disease.

This randomized clinical study included 181 patients with ULMCA lesions who were scheduled to undergo drug-eluting stent implantation. The patients were divided into two groups: 90 patients in the IVUS-guided group and 91 patients in the conventional group. The study evaluated clinical outcomes, procedural characteristics, and the occurrence of MACE for all patients. A multivariate Cox regression analysis was performed to assess the risk reduction associated with IVUS-guided PCI.

Patients who were subjected to IVUS exhibited significantly higher pre-dilatation before stenting (88.9% vs. 72.5%), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3), pressure for post dilatation (18 ± 3 vs. 16 ± 2), and post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49). In terms of 12-month outcomes, patients who received IVUS showed significantly lower MACE compared to those who underwent the conventional method (3.3% vs. 18.7%). Multivariate Cox regression analysis indicated that IVUS was associated with an 84.4% risk reduction in 1-year MACE.

The above study demonstrated that IVUS-guided PCI resulted in enhanced clinical outcomes and substantially lowered the risk of MACE in patients with ULMCA lesions when compared to angiographic-guided PCI.

Cardiac
2 Min Read
14 Jun

Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with ULMCA lesions

According to a recent study, intravascular ultrasonography (IVUS)-guided percutaneous coronary intervention (PCI) has led to enhanced clinical outcomes and a significantly diminished risk of major adverse cardiovascular events (MACE) among patients having unprotected left main coronary artery (ULMCA) lesions . This study’s results were published in the journal, Coronary artery disease.

This randomized clinical study included 181 patients with ULMCA lesions who were scheduled to undergo drug-eluting stent implantation. The patients were divided into two groups: 90 patients in the IVUS-guided group and 91 patients in the conventional group. The study evaluated clinical outcomes, procedural characteristics, and the occurrence of MACE for all patients. A multivariate Cox regression analysis was performed to assess the risk reduction associated with IVUS-guided PCI.

Patients who were subjected to IVUS exhibited significantly higher pre-dilatation before stenting (88.9% vs. 72.5%), stent diameter (3.9 ± 0.4 vs. 3.7 ± 0.3), pressure for post dilatation (18 ± 3 vs. 16 ± 2), and post-dilatation balloon diameter (4.46 ± 0.48 vs. 4.21 ± 0.49). In terms of 12-month outcomes, patients who received IVUS showed significantly lower MACE compared to those who underwent the conventional method (3.3% vs. 18.7%). Multivariate Cox regression analysis indicated that IVUS was associated with an 84.4% risk reduction in 1-year MACE.

The above study demonstrated that IVUS-guided PCI resulted in enhanced clinical outcomes and substantially lowered the risk of MACE in patients with ULMCA lesions when compared to angiographic-guided PCI.

button
Allergy
1 Min Read
13 Jun

Safety and efficacy of Cyclosporine A cationic ophthalmic emulsion in vernal keratoconjunctivitis patients

A recent study found that Cyclosporine A cationic ophthalmic emulsion (CsA CE) was safe, effective, and well tolerated in patients with vernal keratoconjunctivitis (VKC). The results of this study were published in the journal, Eye.

The pooled analysis collected data from 118 and 169 patients (pediatric and adolescent) from the randomized NOVATIVE and VEKTIS trials, respectively. Patients in the NOVATIVE trial were randomized to receive 4 times daily (QID) CsA CE 0.05%, 0.1%, or vehicle eye drops. Those in the VEKTIS trial were administered CsA CE 0.1% QID or twice daily (BID) or vehicle.

Mean ± standard deviation changes in corneal fluorescein staining (CFS) scores for CsA CE from baseline to day 28 were found to be -1.6 ± 1.47 (high-dose), -1.7 ± 1.39 (low-dose), and -1.0 ± 1.55 (vehicle group). Mild to moderate adverse events (AEs) reported were 37.5%, 34.4%, and 37.8% in the high-dose, low-dose, and vehicle groups, respectively.

Hence, it can be concluded from the above results that Cyclosporine A cationic ophthalmic emulsion (CsA CE) may significantly reduce corneal damage, making it safe and well-tolerated in patients with VKC.

Safety and efficacy of Cyclosporine A cationic ophthalmic emulsion in vernal keratoconjunctivitis patients

A recent study found that Cyclosporine A cationic ophthalmic emulsion (CsA CE) was safe, effective, and well tolerated in patients with vernal keratoconjunctivitis (VKC). The results of this study were published in the journal, Eye.

The pooled analysis collected data from 118 and 169 patients (pediatric and adolescent) from the randomized NOVATIVE and VEKTIS trials, respectively. Patients in the NOVATIVE trial were randomized to receive 4 times daily (QID) CsA CE 0.05%, 0.1%, or vehicle eye drops. Those in the VEKTIS trial were administered CsA CE 0.1% QID or twice daily (BID) or vehicle.

Mean ± standard deviation changes in corneal fluorescein staining (CFS) scores for CsA CE from baseline to day 28 were found to be -1.6 ± 1.47 (high-dose), -1.7 ± 1.39 (low-dose), and -1.0 ± 1.55 (vehicle group). Mild to moderate adverse events (AEs) reported were 37.5%, 34.4%, and 37.8% in the high-dose, low-dose, and vehicle groups, respectively.

Hence, it can be concluded from the above results that Cyclosporine A cationic ophthalmic emulsion (CsA CE) may significantly reduce corneal damage, making it safe and well-tolerated in patients with VKC.

Allergy
1 Min Read
13 Jun

Safety and efficacy of Cyclosporine A cationic ophthalmic emulsion in vernal keratoconjunctivitis patients

A recent study found that Cyclosporine A cationic ophthalmic emulsion (CsA CE) was safe, effective, and well tolerated in patients with vernal keratoconjunctivitis (VKC). The results of this study were published in the journal, Eye.

The pooled analysis collected data from 118 and 169 patients (pediatric and adolescent) from the randomized NOVATIVE and VEKTIS trials, respectively. Patients in the NOVATIVE trial were randomized to receive 4 times daily (QID) CsA CE 0.05%, 0.1%, or vehicle eye drops. Those in the VEKTIS trial were administered CsA CE 0.1% QID or twice daily (BID) or vehicle.

Mean ± standard deviation changes in corneal fluorescein staining (CFS) scores for CsA CE from baseline to day 28 were found to be -1.6 ± 1.47 (high-dose), -1.7 ± 1.39 (low-dose), and -1.0 ± 1.55 (vehicle group). Mild to moderate adverse events (AEs) reported were 37.5%, 34.4%, and 37.8% in the high-dose, low-dose, and vehicle groups, respectively.

Hence, it can be concluded from the above results that Cyclosporine A cationic ophthalmic emulsion (CsA CE) may significantly reduce corneal damage, making it safe and well-tolerated in patients with VKC.

button
Oncology
2 Min Read
12 Jun

Significantly greater event-free survival with perioperative durvalumab plus neoadjuvant chemotherapy in Resectable Non-Small-Cell Lung Cancer

According to a recent study, patients with resectable non-small-cell lung cancer (NSCLC) had significantly greater event-free survival and pathological complete response with perioperative durvalumab plus neoadjuvant chemotherapy than with neoadjuvant chemotherapy alone. This study’s findings were published in The New England Journal of Medicine.

This study included 802 patients who were randomly assigned to receive either durvalumab (400 patients) or placebo (402 patients) every 3 weeks for 4 cycles before surgery. This was followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The primary end points of the study were event-free survival and pathological complete response.

At the end of the study, it was found that duration of event-free survival was significantly longer with durvalumab than with placebo. After 1 year, event-free survival was observed in 73.4% and 64.5% of patients in the durvalumab and placebo groups, respectively. Similarly, the incidence of pathological complete response was significantly greater with durvalumab when compared to the placebo. Grade 3 and 4 adverse events occurred in 42.4% and 43.2% of patients in the durvalumab and placebo groups, respectively.

Based on the above results, it can be concluded that perioperative durvalumab plus neoadjuvant chemotherapy may be associated with significantly greater event-free survival and pathological complete response in patients with resectable NSCLC.

Significantly greater event-free survival with perioperative durvalumab plus neoadjuvant chemotherapy in Resectable Non-Small-Cell Lung Cancer

According to a recent study, patients with resectable non-small-cell lung cancer (NSCLC) had significantly greater event-free survival and pathological complete response with perioperative durvalumab plus neoadjuvant chemotherapy than with neoadjuvant chemotherapy alone. This study’s findings were published in The New England Journal of Medicine.

This study included 802 patients who were randomly assigned to receive either durvalumab (400 patients) or placebo (402 patients) every 3 weeks for 4 cycles before surgery. This was followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The primary end points of the study were event-free survival and pathological complete response.

At the end of the study, it was found that duration of event-free survival was significantly longer with durvalumab than with placebo. After 1 year, event-free survival was observed in 73.4% and 64.5% of patients in the durvalumab and placebo groups, respectively. Similarly, the incidence of pathological complete response was significantly greater with durvalumab when compared to the placebo. Grade 3 and 4 adverse events occurred in 42.4% and 43.2% of patients in the durvalumab and placebo groups, respectively.

Based on the above results, it can be concluded that perioperative durvalumab plus neoadjuvant chemotherapy may be associated with significantly greater event-free survival and pathological complete response in patients with resectable NSCLC.

Oncology
2 Min Read
12 Jun

Significantly greater event-free survival with perioperative durvalumab plus neoadjuvant chemotherapy in Resectable Non-Small-Cell Lung Cancer

According to a recent study, patients with resectable non-small-cell lung cancer (NSCLC) had significantly greater event-free survival and pathological complete response with perioperative durvalumab plus neoadjuvant chemotherapy than with neoadjuvant chemotherapy alone. This study’s findings were published in The New England Journal of Medicine.

This study included 802 patients who were randomly assigned to receive either durvalumab (400 patients) or placebo (402 patients) every 3 weeks for 4 cycles before surgery. This was followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The primary end points of the study were event-free survival and pathological complete response.

At the end of the study, it was found that duration of event-free survival was significantly longer with durvalumab than with placebo. After 1 year, event-free survival was observed in 73.4% and 64.5% of patients in the durvalumab and placebo groups, respectively. Similarly, the incidence of pathological complete response was significantly greater with durvalumab when compared to the placebo. Grade 3 and 4 adverse events occurred in 42.4% and 43.2% of patients in the durvalumab and placebo groups, respectively.

Based on the above results, it can be concluded that perioperative durvalumab plus neoadjuvant chemotherapy may be associated with significantly greater event-free survival and pathological complete response in patients with resectable NSCLC.

button
Cardiac
2 Min Read
11 Jun

Safety and efficacy of dapagliflozin in acute heart failure patients

According to a recent study, the early administration of dapagliflozin during hospitalization for acute heart failure (AHF) is considered safe and fulfills a component of guideline-directed medical therapy (GDMT) optimization. Additionally, dapagliflozin has been associated with evidence indicating enhanced diuresis in individuals with AHF. This study’s findings were published in the Journal of the American College of Cardiology.

In this open-label, multicenter trial, 240 patients were randomly assigned within one day of hospital presentation for hypervolemic AHF to either structured usual care with the protocol of diuretic titration until the 5th day or dapagliflozin 10 mg once daily or discharge from hospital. The primary outcome of the study, diuretic efficiency indicated by cumulative weight change per cumulative loop diuretic dose, was compared between treatment groups using a proportional odds model adjusted for initial weight.

There was no difference observed in terms of diuretic efficiency between dapagliflozin and standard care. Dapagliflozin resulted in lower loop diuretic doses (560 mg [Q1-Q3: 260-1,150 mg] compared with 800 mg [Q1-Q3: 380-1,715 mg]) and fewer intravenous diuretic up-titrations to achieve similar weight loss compared to standard care. Initiating dapagliflozin early did not lead to an increase in adverse events related to diabetes, heart health, or kidney function. Additionally, dapagliflozin was linked to enhanced median 24-hour natriuresis and urine output, facilitating quicker hospital discharge during the study period.

Thus, it can be concluded that the administration of dapagliflozin at an early stage during hospitalization for AHF is regarded as a safe practice and fulfills a component of optimizing GDMT. Additionally, there is evidence indicating that dapagliflozin promotes enhanced diuresis in individuals with AHF.

Safety and efficacy of dapagliflozin in acute heart failure patients

According to a recent study, the early administration of dapagliflozin during hospitalization for acute heart failure (AHF) is considered safe and fulfills a component of guideline-directed medical therapy (GDMT) optimization. Additionally, dapagliflozin has been associated with evidence indicating enhanced diuresis in individuals with AHF. This study’s findings were published in the Journal of the American College of Cardiology.

In this open-label, multicenter trial, 240 patients were randomly assigned within one day of hospital presentation for hypervolemic AHF to either structured usual care with the protocol of diuretic titration until the 5th day or dapagliflozin 10 mg once daily or discharge from hospital. The primary outcome of the study, diuretic efficiency indicated by cumulative weight change per cumulative loop diuretic dose, was compared between treatment groups using a proportional odds model adjusted for initial weight.

There was no difference observed in terms of diuretic efficiency between dapagliflozin and standard care. Dapagliflozin resulted in lower loop diuretic doses (560 mg [Q1-Q3: 260-1,150 mg] compared with 800 mg [Q1-Q3: 380-1,715 mg]) and fewer intravenous diuretic up-titrations to achieve similar weight loss compared to standard care. Initiating dapagliflozin early did not lead to an increase in adverse events related to diabetes, heart health, or kidney function. Additionally, dapagliflozin was linked to enhanced median 24-hour natriuresis and urine output, facilitating quicker hospital discharge during the study period.

Thus, it can be concluded that the administration of dapagliflozin at an early stage during hospitalization for AHF is regarded as a safe practice and fulfills a component of optimizing GDMT. Additionally, there is evidence indicating that dapagliflozin promotes enhanced diuresis in individuals with AHF.

Cardiac
2 Min Read
11 Jun

Safety and efficacy of dapagliflozin in acute heart failure patients

According to a recent study, the early administration of dapagliflozin during hospitalization for acute heart failure (AHF) is considered safe and fulfills a component of guideline-directed medical therapy (GDMT) optimization. Additionally, dapagliflozin has been associated with evidence indicating enhanced diuresis in individuals with AHF. This study’s findings were published in the Journal of the American College of Cardiology.

In this open-label, multicenter trial, 240 patients were randomly assigned within one day of hospital presentation for hypervolemic AHF to either structured usual care with the protocol of diuretic titration until the 5th day or dapagliflozin 10 mg once daily or discharge from hospital. The primary outcome of the study, diuretic efficiency indicated by cumulative weight change per cumulative loop diuretic dose, was compared between treatment groups using a proportional odds model adjusted for initial weight.

There was no difference observed in terms of diuretic efficiency between dapagliflozin and standard care. Dapagliflozin resulted in lower loop diuretic doses (560 mg [Q1-Q3: 260-1,150 mg] compared with 800 mg [Q1-Q3: 380-1,715 mg]) and fewer intravenous diuretic up-titrations to achieve similar weight loss compared to standard care. Initiating dapagliflozin early did not lead to an increase in adverse events related to diabetes, heart health, or kidney function. Additionally, dapagliflozin was linked to enhanced median 24-hour natriuresis and urine output, facilitating quicker hospital discharge during the study period.

Thus, it can be concluded that the administration of dapagliflozin at an early stage during hospitalization for AHF is regarded as a safe practice and fulfills a component of optimizing GDMT. Additionally, there is evidence indicating that dapagliflozin promotes enhanced diuresis in individuals with AHF.

button
Analgesia
2 Min Read
10 Jun

Analgesic effect of perineural and intravenous betamethasone following knee arthroplasty

According to a recent study, the use of perineural and intravenous betamethasone resulted in a heightened analgesic effect after knee arthroplasty. Moreover, it was linked to reduced levels of TNF-α, IL-1β, and HS-CRP, as well as improved knee range of motion (ROM), which may lead to early ambulation and postoperative rehabilitation subsequent to knee arthroplasty. This study’s findings were published in the journal, Orthopaedic surgery .

In this randomized, controlled study, a total of 159 patients undergoing knee arthroplasty were divided into three groups. The NS group was administered intravenous 3mL 0.9% normal saline and ropivacaine 0.375%, the PNB group received ropivacaine 0.375% along with intravenous 3mL 0.9% normal saline and perineural betamethasone (12mg) 3mL, while the IVB group was given intravenous betamethasone (12mg) 3mL and ropivacaine 0.375%.

Improved median (IQR) numeric rating scale (NRS) scores on the six meter walk test were observed in both the perineural and intravenous administration of betamethasone. The scores for both groups were 1.0 (1.0-2.0), while the NS group had a score of 2.0 (1.0-2.0). Both the IVB groups and PNB indicated significant reductions in NRS scores 24 and 36 hours following surgery when compared to the NS group. There was a significant increase in range of motion at 24, 36, and 48 hours post-operation in both the IVB and PNB groups. Also, the PNB and IVB groups presented lower levels of cytokine TNF-α and IL-1β in fluid samples, as well as a lower level of HS-CRP in blood samples, in comparison to the NS group.

Thus, it can be concluded that the administration of perineural and intravenous betamethasone following knee arthroplasty led to an enhanced analgesic outcome. Additionally, it was associated with decreased levels of TNF-α, IL-1β, and HS-CRP, along with improved knee ROM.

Analgesic effect of perineural and intravenous betamethasone following knee arthroplasty

According to a recent study, the use of perineural and intravenous betamethasone resulted in a heightened analgesic effect after knee arthroplasty. Moreover, it was linked to reduced levels of TNF-α, IL-1β, and HS-CRP, as well as improved knee range of motion (ROM), which may lead to early ambulation and postoperative rehabilitation subsequent to knee arthroplasty. This study’s findings were published in the journal, Orthopaedic surgery .

In this randomized, controlled study, a total of 159 patients undergoing knee arthroplasty were divided into three groups. The NS group was administered intravenous 3mL 0.9% normal saline and ropivacaine 0.375%, the PNB group received ropivacaine 0.375% along with intravenous 3mL 0.9% normal saline and perineural betamethasone (12mg) 3mL, while the IVB group was given intravenous betamethasone (12mg) 3mL and ropivacaine 0.375%.

Improved median (IQR) numeric rating scale (NRS) scores on the six meter walk test were observed in both the perineural and intravenous administration of betamethasone. The scores for both groups were 1.0 (1.0-2.0), while the NS group had a score of 2.0 (1.0-2.0). Both the IVB groups and PNB indicated significant reductions in NRS scores 24 and 36 hours following surgery when compared to the NS group. There was a significant increase in range of motion at 24, 36, and 48 hours post-operation in both the IVB and PNB groups. Also, the PNB and IVB groups presented lower levels of cytokine TNF-α and IL-1β in fluid samples, as well as a lower level of HS-CRP in blood samples, in comparison to the NS group.

Thus, it can be concluded that the administration of perineural and intravenous betamethasone following knee arthroplasty led to an enhanced analgesic outcome. Additionally, it was associated with decreased levels of TNF-α, IL-1β, and HS-CRP, along with improved knee ROM.

Analgesia
2 Min Read
10 Jun

Analgesic effect of perineural and intravenous betamethasone following knee arthroplasty

According to a recent study, the use of perineural and intravenous betamethasone resulted in a heightened analgesic effect after knee arthroplasty. Moreover, it was linked to reduced levels of TNF-α, IL-1β, and HS-CRP, as well as improved knee range of motion (ROM), which may lead to early ambulation and postoperative rehabilitation subsequent to knee arthroplasty. This study’s findings were published in the journal, Orthopaedic surgery .

In this randomized, controlled study, a total of 159 patients undergoing knee arthroplasty were divided into three groups. The NS group was administered intravenous 3mL 0.9% normal saline and ropivacaine 0.375%, the PNB group received ropivacaine 0.375% along with intravenous 3mL 0.9% normal saline and perineural betamethasone (12mg) 3mL, while the IVB group was given intravenous betamethasone (12mg) 3mL and ropivacaine 0.375%.

Improved median (IQR) numeric rating scale (NRS) scores on the six meter walk test were observed in both the perineural and intravenous administration of betamethasone. The scores for both groups were 1.0 (1.0-2.0), while the NS group had a score of 2.0 (1.0-2.0). Both the IVB groups and PNB indicated significant reductions in NRS scores 24 and 36 hours following surgery when compared to the NS group. There was a significant increase in range of motion at 24, 36, and 48 hours post-operation in both the IVB and PNB groups. Also, the PNB and IVB groups presented lower levels of cytokine TNF-α and IL-1β in fluid samples, as well as a lower level of HS-CRP in blood samples, in comparison to the NS group.

Thus, it can be concluded that the administration of perineural and intravenous betamethasone following knee arthroplasty led to an enhanced analgesic outcome. Additionally, it was associated with decreased levels of TNF-α, IL-1β, and HS-CRP, along with improved knee ROM.

button
Allergy
2 Min Read
07 Jun

Omalizumab in the treatment of various food allergies

A recent study showed the superiority of omalizumab treatment for 16 weeks compared to a placebo in increasing the reaction threshold for peanut and other common food allergens in individuals as young as 1 year old with multiple food allergies. This study’s findings were published in The New England journal of medicine.

In this trial a total of 180 participants were randomly assigned in a 2:1 ratio to receive either omalizumab or placebo subcutaneously every 2 to 4 weeks for 16 to 20 weeks. The dosage was determined based on their weight and IgE levels. After this initial treatment period, the challenges were repeated. The primary endpoint of the study was ingestion of a single dose of 600 mg or more of peanut protein without experiencing any dose-limiting symptoms. The three key secondary endpoints were the participants' ability to consume milk, cashew, and egg in single doses of at least 1000 mg each without experiencing any dose-limiting symptoms.

The primary end-point criteria were met by 79 out of 118 participants (67%) who received omalizumab, in contrast to only 4 out of 59 participants (7%) who received placebo. Results for the key secondary end points were consistent with those of the primary end point, with significant differences observed in the percentages for cashew (41% vs. 3%), milk (66% vs. 10%), and egg (67% vs. 0%). Safety end points did not exhibit any significant differences between the groups, except for a higher number of injection-site reactions in the omalizumab group.

The above results conclude that among individuals with multiple food allergies, omalizumab treatment for 16 weeks may be superior to placebo in enhancing the reaction threshold for peanut and other common food allergens.

Omalizumab in the treatment of various food allergies

A recent study showed the superiority of omalizumab treatment for 16 weeks compared to a placebo in increasing the reaction threshold for peanut and other common food allergens in individuals as young as 1 year old with multiple food allergies. This study’s findings were published in The New England journal of medicine.

In this trial a total of 180 participants were randomly assigned in a 2:1 ratio to receive either omalizumab or placebo subcutaneously every 2 to 4 weeks for 16 to 20 weeks. The dosage was determined based on their weight and IgE levels. After this initial treatment period, the challenges were repeated. The primary endpoint of the study was ingestion of a single dose of 600 mg or more of peanut protein without experiencing any dose-limiting symptoms. The three key secondary endpoints were the participants' ability to consume milk, cashew, and egg in single doses of at least 1000 mg each without experiencing any dose-limiting symptoms.

The primary end-point criteria were met by 79 out of 118 participants (67%) who received omalizumab, in contrast to only 4 out of 59 participants (7%) who received placebo. Results for the key secondary end points were consistent with those of the primary end point, with significant differences observed in the percentages for cashew (41% vs. 3%), milk (66% vs. 10%), and egg (67% vs. 0%). Safety end points did not exhibit any significant differences between the groups, except for a higher number of injection-site reactions in the omalizumab group.

The above results conclude that among individuals with multiple food allergies, omalizumab treatment for 16 weeks may be superior to placebo in enhancing the reaction threshold for peanut and other common food allergens.

Allergy
2 Min Read
07 Jun

Omalizumab in the treatment of various food allergies

A recent study showed the superiority of omalizumab treatment for 16 weeks compared to a placebo in increasing the reaction threshold for peanut and other common food allergens in individuals as young as 1 year old with multiple food allergies. This study’s findings were published in The New England journal of medicine.

In this trial a total of 180 participants were randomly assigned in a 2:1 ratio to receive either omalizumab or placebo subcutaneously every 2 to 4 weeks for 16 to 20 weeks. The dosage was determined based on their weight and IgE levels. After this initial treatment period, the challenges were repeated. The primary endpoint of the study was ingestion of a single dose of 600 mg or more of peanut protein without experiencing any dose-limiting symptoms. The three key secondary endpoints were the participants' ability to consume milk, cashew, and egg in single doses of at least 1000 mg each without experiencing any dose-limiting symptoms.

The primary end-point criteria were met by 79 out of 118 participants (67%) who received omalizumab, in contrast to only 4 out of 59 participants (7%) who received placebo. Results for the key secondary end points were consistent with those of the primary end point, with significant differences observed in the percentages for cashew (41% vs. 3%), milk (66% vs. 10%), and egg (67% vs. 0%). Safety end points did not exhibit any significant differences between the groups, except for a higher number of injection-site reactions in the omalizumab group.

The above results conclude that among individuals with multiple food allergies, omalizumab treatment for 16 weeks may be superior to placebo in enhancing the reaction threshold for peanut and other common food allergens.

button
Oncology
2 Min Read
06 Jun

Better outcomes with combination therapy of nivolumab plus gemcitabine-cisplatin in untreated advanced urothelial carcinoma

According to a recent study, combination therapy with nivolumab plus gemcitabine-cisplatin yielded significantly better outcomes in patients with previously untreated advanced urothelial carcinoma when compared to gemcitabine-cisplatin alone. This study’s findings were published in The New England Journal of Medicine.

This phase 3, multinational, open-label trial included 608 patients with previously untreated unresectable or metastatic urothelial carcinoma. They were randomly assigned to receive either 360mg of intravenous nivolumab plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up to 6 cycles, and later on, 480mg nivolumab every 4 weeks for a maximum of 2 years or gemcitabine-cisplatin alone every 3 weeks for up to 6 cycles. The primary outcomes of the study were overall and progression-free survival.

At the median follow-up of 33.6 months, it was observed that with nivolumab-combination therapy (21.7 months), overall survival was longer than with gemcitabine-cisplatin alone (18.9). Similarly, progression-free survival was also longer with nivolumab-combination therapy at 7.9 months compared to 7.6 months with gemcitabine-cisplatin alone (hazard ratio for progression or death,0.72; 95% Cl, 0.59 to 0.88; P = 0.001). At the end of one year, the progression-free survival was 34.2% for nivolumab-combination therapy and 21.8% for gemcitabine-cisplatin alone.

From the above findings, it can be concluded that combination therapy with nivolumab plus gemcitabine-cisplatin may result in significantly better outcomes in patients with previously untreated advanced urothelial carcinoma.

Better outcomes with combination therapy of nivolumab plus gemcitabine-cisplatin in untreated advanced urothelial carcinoma

According to a recent study, combination therapy with nivolumab plus gemcitabine-cisplatin yielded significantly better outcomes in patients with previously untreated advanced urothelial carcinoma when compared to gemcitabine-cisplatin alone. This study’s findings were published in The New England Journal of Medicine.

This phase 3, multinational, open-label trial included 608 patients with previously untreated unresectable or metastatic urothelial carcinoma. They were randomly assigned to receive either 360mg of intravenous nivolumab plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up to 6 cycles, and later on, 480mg nivolumab every 4 weeks for a maximum of 2 years or gemcitabine-cisplatin alone every 3 weeks for up to 6 cycles. The primary outcomes of the study were overall and progression-free survival.

At the median follow-up of 33.6 months, it was observed that with nivolumab-combination therapy (21.7 months), overall survival was longer than with gemcitabine-cisplatin alone (18.9). Similarly, progression-free survival was also longer with nivolumab-combination therapy at 7.9 months compared to 7.6 months with gemcitabine-cisplatin alone (hazard ratio for progression or death,0.72; 95% Cl, 0.59 to 0.88; P = 0.001). At the end of one year, the progression-free survival was 34.2% for nivolumab-combination therapy and 21.8% for gemcitabine-cisplatin alone.

From the above findings, it can be concluded that combination therapy with nivolumab plus gemcitabine-cisplatin may result in significantly better outcomes in patients with previously untreated advanced urothelial carcinoma.

Oncology
2 Min Read
06 Jun

Better outcomes with combination therapy of nivolumab plus gemcitabine-cisplatin in untreated advanced urothelial carcinoma

According to a recent study, combination therapy with nivolumab plus gemcitabine-cisplatin yielded significantly better outcomes in patients with previously untreated advanced urothelial carcinoma when compared to gemcitabine-cisplatin alone. This study’s findings were published in The New England Journal of Medicine.

This phase 3, multinational, open-label trial included 608 patients with previously untreated unresectable or metastatic urothelial carcinoma. They were randomly assigned to receive either 360mg of intravenous nivolumab plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up to 6 cycles, and later on, 480mg nivolumab every 4 weeks for a maximum of 2 years or gemcitabine-cisplatin alone every 3 weeks for up to 6 cycles. The primary outcomes of the study were overall and progression-free survival.

At the median follow-up of 33.6 months, it was observed that with nivolumab-combination therapy (21.7 months), overall survival was longer than with gemcitabine-cisplatin alone (18.9). Similarly, progression-free survival was also longer with nivolumab-combination therapy at 7.9 months compared to 7.6 months with gemcitabine-cisplatin alone (hazard ratio for progression or death,0.72; 95% Cl, 0.59 to 0.88; P = 0.001). At the end of one year, the progression-free survival was 34.2% for nivolumab-combination therapy and 21.8% for gemcitabine-cisplatin alone.

From the above findings, it can be concluded that combination therapy with nivolumab plus gemcitabine-cisplatin may result in significantly better outcomes in patients with previously untreated advanced urothelial carcinoma.

button
Neuro
1 Min Read
04 Jun

Efficacy and safety of tenecteplase versus alteplase in stroke patients with carotid tandem lesions

According to a recent study, in individuals with carotid tandem lesions (TL) treated with endovascular thrombectomy (EVT), the administration of intravenous tenecteplase may result in comparable or improved clinical outcomes, similar rates of angiographic reperfusion, and equivalent safety outcomes when compared to alteplase. This study’s findings were published in the International journal of stroke.

This substudy of the alteplase versus tenecteplase trial included 1577 patients, with 18.8% (128 patients) having carotid TL. Among these patients, 72.7%(93) underwent intravenous thrombolysis (IVT) plus EVT, whereas 27.3% (35) were treated with IVT alone. The primary outcome of the study included a 90-day-modified Rankin Scale (mRS) 0-1 and secondary outcomes included mRS 0-2, symptomatic ICH (sICH), and mortality.

Tenecteplase in the IVT + EVT group exhibited higher odds of 90-day-mRS 0-1 outcome (46.0% vs. 32.6%, adjusted OR (aOR) 3.21) when compared to alteplase. Additionally, only one patient experienced SICH.

The above study demonstrated that in individuals with carotid TL treated with EVT, the administration of intravenous tenecteplase may yield comparable or improved clinical outcomes, similar rates of angiographic reperfusion, and equivalent safety outcomes when compared to alteplase.

Efficacy and safety of tenecteplase versus alteplase in stroke patients with carotid tandem lesions

According to a recent study, in individuals with carotid tandem lesions (TL) treated with endovascular thrombectomy (EVT), the administration of intravenous tenecteplase may result in comparable or improved clinical outcomes, similar rates of angiographic reperfusion, and equivalent safety outcomes when compared to alteplase. This study’s findings were published in the International journal of stroke.

This substudy of the alteplase versus tenecteplase trial included 1577 patients, with 18.8% (128 patients) having carotid TL. Among these patients, 72.7%(93) underwent intravenous thrombolysis (IVT) plus EVT, whereas 27.3% (35) were treated with IVT alone. The primary outcome of the study included a 90-day-modified Rankin Scale (mRS) 0-1 and secondary outcomes included mRS 0-2, symptomatic ICH (sICH), and mortality.

Tenecteplase in the IVT + EVT group exhibited higher odds of 90-day-mRS 0-1 outcome (46.0% vs. 32.6%, adjusted OR (aOR) 3.21) when compared to alteplase. Additionally, only one patient experienced SICH.

The above study demonstrated that in individuals with carotid TL treated with EVT, the administration of intravenous tenecteplase may yield comparable or improved clinical outcomes, similar rates of angiographic reperfusion, and equivalent safety outcomes when compared to alteplase.

Neuro
1 Min Read
04 Jun

Efficacy and safety of tenecteplase versus alteplase in stroke patients with carotid tandem lesions

According to a recent study, in individuals with carotid tandem lesions (TL) treated with endovascular thrombectomy (EVT), the administration of intravenous tenecteplase may result in comparable or improved clinical outcomes, similar rates of angiographic reperfusion, and equivalent safety outcomes when compared to alteplase. This study’s findings were published in the International journal of stroke.

This substudy of the alteplase versus tenecteplase trial included 1577 patients, with 18.8% (128 patients) having carotid TL. Among these patients, 72.7%(93) underwent intravenous thrombolysis (IVT) plus EVT, whereas 27.3% (35) were treated with IVT alone. The primary outcome of the study included a 90-day-modified Rankin Scale (mRS) 0-1 and secondary outcomes included mRS 0-2, symptomatic ICH (sICH), and mortality.

Tenecteplase in the IVT + EVT group exhibited higher odds of 90-day-mRS 0-1 outcome (46.0% vs. 32.6%, adjusted OR (aOR) 3.21) when compared to alteplase. Additionally, only one patient experienced SICH.

The above study demonstrated that in individuals with carotid TL treated with EVT, the administration of intravenous tenecteplase may yield comparable or improved clinical outcomes, similar rates of angiographic reperfusion, and equivalent safety outcomes when compared to alteplase.

button
1539 Resources in

Videos

View all
422 Resources in

Webinars

View all
1 Resources in

Courses

View all